Several other brokerages have also recently issued reports on LLY. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the stock a hold rating in a report on Friday, October 6th. Piper Jaffray Companies reiterated a buy rating and set a $105.00 target price on shares of Eli Lilly and in a report on Friday, October 13th. Jefferies Group reiterated a buy rating and set a $89.00 target price (down from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Goldman Sachs Group reiterated a buy rating and set a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Finally, Zacks Investment Research upgraded shares of Eli Lilly and from a hold rating to a buy rating and set a $95.00 target price on the stock in a report on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $90.25.
Eli Lilly and (NYSE LLY) traded up $0.48 during midday trading on Tuesday, hitting $86.06. 3,876,700 shares of the stock were exchanged, compared to its average volume of 3,672,667. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $94,231.72, a PE ratio of 20.92, a PEG ratio of 1.88 and a beta of 0.35. Eli Lilly and has a 12-month low of $66.39 and a 12-month high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.88 earnings per share. research analysts forecast that Eli Lilly and will post 4.21 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.42%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s payout ratio is currently 98.58%.
In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $85.14, for a total transaction of $16,602,300.00. Following the transaction, the insider now directly owns 123,513,247 shares of the company’s stock, valued at $10,515,917,849.58. The disclosure for this sale can be found here. Insiders sold a total of 628,588 shares of company stock valued at $53,399,536 over the last ninety days. 0.20% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Airain ltd purchased a new position in shares of Eli Lilly and during the 2nd quarter valued at approximately $567,000. Buckingham Asset Management LLC increased its holdings in shares of Eli Lilly and by 21.3% during the 2nd quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock valued at $266,000 after purchasing an additional 568 shares in the last quarter. BSW Wealth Partners increased its holdings in shares of Eli Lilly and by 0.6% during the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock valued at $393,000 after purchasing an additional 27 shares in the last quarter. Sumitomo Life Insurance Co. increased its holdings in shares of Eli Lilly and by 4.4% during the 2nd quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock valued at $2,675,000 after purchasing an additional 1,370 shares in the last quarter. Finally, Mirador Capital Partners LP increased its holdings in shares of Eli Lilly and by 5.3% during the 2nd quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock valued at $1,011,000 after purchasing an additional 619 shares in the last quarter. 76.43% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Eli Lilly and (LLY) Given a $73.00 Price Target at BMO Capital Markets” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://ledgergazette.com/2017/12/06/eli-lilly-and-lly-given-a-73-00-price-target-at-bmo-capital-markets.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.